Adcetris Earns Orphan Drug Status for Mycosis Fungoides
Seattle Genetics, makers of the anti-CD30 treatment Adcetris for Hodgkin's lymphoma and anaplastic large cell lymphoma announced last week that the company has secured orphan drug status for Adcetris for a new indication.
The indication is for the cutaneous T-cell lymphoma mycosis fungoides (MF), the most commonly diagnosed cutaneous T-cell lymphoma. Orphan drug status means that if the U.S. Food and Drug Administration eventually approves Adcetris for MF, the agency will not approve other similar products for MF for seven years, granting the company market exclusivity.
Seattle Genetics has been working to find a broader market for Adcetris, and clearly this move is another step in that direction.
Source: Business Week
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
